{
  "case_id": "Case_11",
  "model_id": "x-ai/grok-2-1212",
  "content": "{\n    \"primary_diagnosis\": {\n        \"name\": \"Acquired Hemolytic Anemia due to Drug-Induced Hemolysis\",\n        \"confidence\": 0.8,\n        \"icd_code\": \"D59.0\",\n        \"reasoning\": \"Patient's symptoms of jaundice, dark urine, fatigue, and splenomegaly along with recent initiation of semaglutide suggest drug-induced hemolysis. Middle Eastern origin increases risk of G6PD deficiency, which could exacerbate hemolysis.\"\n    },\n    \"differential_diagnoses\": [\n        {\n            \"name\": \"G6PD Deficiency\",\n            \"confidence\": 0.7,\n            \"icd_code\": \"D55.0\",\n            \"reasoning\": \"High prevalence in Middle Eastern populations; symptoms consistent with hemolytic crisis potentially triggered by medication.\"\n        },\n        {\n            \"name\": \"Autoimmune Hemolytic Anemia\",\n            \"confidence\": 0.5,\n            \"icd_code\": \"D59.1\",\n            \"reasoning\": \"Presents similarly to drug-induced hemolysis but lacks clear medication trigger; could be underlying condition.\"\n        },\n        {\n            \"name\": \"Hepatitis\",\n            \"confidence\": 0.4,\n            \"icd_code\": \"B15-B19\",\n            \"reasoning\": \"Jaundice and fatigue could be indicative of liver disease, though less likely without additional liver function abnormalities.\"\n        }\n    ],\n    \"key_findings\": [\n        \"Jaundice and dark urine indicating hemolysis\",\n        \"Recent initiation of semaglutide\"\n    ],\n    \"diagnostic_tests\": [\n        {\n            \"test\": \"Complete Blood Count (CBC) with reticulocyte count\",\n            \"purpose\": \"Assess for anemia and hemolysis\",\n            \"priority\": \"immediate\"\n        },\n        {\n            \"test\": \"Direct Coombs Test\",\n            \"purpose\": \"Rule in/out autoimmune hemolytic anemia\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"G6PD enzyme activity test\",\n            \"purpose\": \"Rule in/out G6PD deficiency\",\n            \"priority\": \"urgent\"\n        },\n        {\n            \"test\": \"Liver function tests\",\n            \"purpose\": \"Rule out hepatitis or other liver disease\",\n            \"priority\": \"routine\"\n        }\n    ],\n    \"management_plan\": {\n        \"immediate_actions\": [\n            \"Discontinue semaglutide\",\n            \"Initiate supportive care with IV fluids\"\n        ],\n        \"medications\": [\n            {\n                \"drug\": \"Folic Acid\",\n                \"dose\": \"1 mg\",\n                \"route\": \"PO\",\n                \"duration\": \"daily\",\n                \"rationale\": \"Support erythropoiesis in hemolysis\"\n            }\n        ],\n        \"monitoring\": [\n            \"Hemoglobin levels\",\n            \"Daily until stable\"\n        ],\n        \"consultations\": [\n            {\n                \"specialty\": \"Hematology\",\n                \"urgency\": \"urgent\",\n                \"reason\": \"Expertise in hemolytic disorders and management\"\n            }\n        ]\n    },\n    \"red_flags\": [\n        \"Severe anemia requiring transfusion\",\n        \"Signs of acute kidney injury from hemolysis\"\n    ],\n    \"patient_education\": [\n        \"Importance of reporting new medications and symptoms\",\n        \"Potential genetic predispositions requiring family screening\"\n    ],\n    \"follow_up\": {\n        \"timing\": \"Within 1 week after initial stabilization\",\n        \"conditions\": \"Worsening symptoms, severe anemia, or new signs of organ dysfunction\"\n    },\n    \"confidence_in_assessment\": 0.8,\n    \"uncertainties\": [\n        \"Exact cause of hemolysis without test results\",\n        \"Potential underlying genetic conditions not yet identified\"\n    ]\n}",
  "latency": 9.332468032836914,
  "timestamp": "2025-08-10T01:32:15.431354",
  "cached_at": "2025-08-10T01:32:15.431359"
}